ATE459646T1 - Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist - Google Patents

Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Info

Publication number
ATE459646T1
ATE459646T1 AT02775586T AT02775586T ATE459646T1 AT E459646 T1 ATE459646 T1 AT E459646T1 AT 02775586 T AT02775586 T AT 02775586T AT 02775586 T AT02775586 T AT 02775586T AT E459646 T1 ATE459646 T1 AT E459646T1
Authority
AT
Austria
Prior art keywords
deletion
exon
detection
diagnostic method
csf
Prior art date
Application number
AT02775586T
Other languages
English (en)
Inventor
Sang-Yup Lee
Ki-Jun Jeong
Hyun-Cheol Chung
Nae-Choon Yoo
Ki-Chang Keum
Won-Min Yoo
Original Assignee
Medigenes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigenes filed Critical Medigenes
Application granted granted Critical
Publication of ATE459646T1 publication Critical patent/ATE459646T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02775586T 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist ATE459646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010060826 2001-09-28
PCT/KR2002/001825 WO2003027288A1 (en) 2001-09-28 2002-09-28 Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3

Publications (1)

Publication Number Publication Date
ATE459646T1 true ATE459646T1 (de) 2010-03-15

Family

ID=19714831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775586T ATE459646T1 (de) 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Country Status (9)

Country Link
US (10) US20040247562A1 (de)
EP (1) EP1446485B1 (de)
JP (1) JP4413611B2 (de)
KR (2) KR100523328B1 (de)
CN (1) CN100491527C (de)
AT (1) ATE459646T1 (de)
AU (1) AU2002343900B2 (de)
DE (1) DE60235568D1 (de)
WO (1) WO2003027288A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067170A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
KR20070019524A (ko) * 2005-08-12 2007-02-15 메디제네스(주) 암 진단 마커 및 방법
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
CN102906108B (zh) 2010-03-04 2016-01-20 菲尼克斯公司 用于无变性制备可溶性重组干扰素蛋白的方法
PL2552949T3 (pl) 2010-04-01 2017-01-31 Pfenex Inc. Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5777193A (en) * 1994-03-04 1998-07-07 Ludwig Institute For Cancer Research Animals with targeted gene disruption
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
KR100365482B1 (ko) 1999-12-28 2002-12-26 철 근 김 종양 억제 유전자의 프라이머쌍을 포함하는 암 진단용 벡터

Also Published As

Publication number Publication date
CN100491527C (zh) 2009-05-27
AU2002343900B2 (en) 2007-04-26
JP2005503810A (ja) 2005-02-10
JP4413611B2 (ja) 2010-02-10
US20050170416A1 (en) 2005-08-04
US20050244856A1 (en) 2005-11-03
KR100716014B1 (ko) 2007-05-08
US20140005365A1 (en) 2014-01-02
US20100286381A1 (en) 2010-11-11
KR100523328B1 (ko) 2005-10-24
US8324363B2 (en) 2012-12-04
EP1446485B1 (de) 2010-03-03
CN1561395A (zh) 2005-01-05
WO2003027288A1 (en) 2003-04-03
US20120322684A1 (en) 2012-12-20
US20050266430A1 (en) 2005-12-01
US20040247562A1 (en) 2004-12-09
EP1446485A1 (de) 2004-08-18
US20050158810A1 (en) 2005-07-21
US20050170417A1 (en) 2005-08-04
WO2003027288A9 (en) 2003-06-05
DE60235568D1 (de) 2010-04-15
KR20030027870A (ko) 2003-04-07
EP1446485A4 (de) 2005-05-25
KR20050098821A (ko) 2005-10-12
US20120329078A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
Bernardes et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19
Schmidt et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
Baba et al. A novel allelic variant of serum amyloic A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA–amyloidosis
JP2006500016A5 (de)
DE69521813D1 (de) Verfahrens und testsätze zur diagnose periodentahlkrankheiten und zur vorhersage des risikos der progression davon
US11579140B2 (en) Methods related to bronchial premalignant lesion severity and progression
ATE350486T1 (de) Durch mechanischen stress induzierte gene, deren expressionsprodukte und deren verwendung.
DE69518558T2 (de) Verfahren zur Diagnose von Krebs oder Präkanzerose durch Nachweis IRF-1-spezifischer RNS
EP0960214A1 (de) Diagnose des Krankheitszustandesan HAnd von mRNA-Profilen
TW201734454A (zh) 檢測膀胱癌之尿液標記物
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
DE60239089D1 (de) Verfahren zur Diagnose von Krebserkrankungen durch Messung der TIMP-1-Glycosylationsveränderungen im Zusammenhang mit der Tumorgenese und Metastasen
ATE403743T1 (de) Genetische veränderungen, die mit lungencarzinomen korrelieren
MXPA05011008A (es) Medios y metodos para diagnosticar y tratar trastornos afectivos.
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
ATE459646T1 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
KR102112951B1 (ko) 암의 진단을 위한 ngs 방법
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
ATE483019T1 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
CA2827506A1 (en) Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
EP2768975B1 (de) Epigenetischer marker zur identifikation von il17-positiven t-zellen in komplexen proben
DE602004024300D1 (de) Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
ATE369426T1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
Caetano et al. Mapping the Spatial Dynamics of the Human Oral Mucosa in Chronic Inflammatory Disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties